Catalyst Pharmaceuticals, Inc. (FRA:CN2)

Market Cap	2.89B +19.0%
Revenue (ttm)	501.64M +19.8%
Net Income	182.54M +30.8%
EPS	1.43 +28.2%
Shares Out	n/a
PE Ratio	15.81
Forward PE	9.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	17
Open	23.40
Previous Close	21.80
Day's Range	23.40 - 23.40
52-Week Range	16.15 - 23.40
Beta	n/a
RSI	58.91
Earnings Date	May 6, 2026

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticoste...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 182
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CN2

Financial Performance

In 2025, Catalyst Pharmaceuticals's revenue was $588.99 million, an increase of 19.78% compared to the previous year's $491.73 million. Earnings were $214.33 million, an increase of 30.78%.

Financial numbers in USD